Edwards Lifesciences (NYSE:EW) Raised to Outperform at Wolfe Research

Edwards Lifesciences (NYSE:EW) was upgraded by stock analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a research note issued on Wednesday,Finviz reports. The firm presently has a $92.00 price objective on the medical research company’s stock. Wolfe Research’s price objective points to a potential upside of 14.91% from the company’s current price.

Several other analysts have also recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Barclays reaffirmed an “overweight” rating and issued a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Wednesday, December 17th. Finally, BTIG Research restated a “buy” rating and issued a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $95.96.

Edwards Lifesciences Stock Up 0.7%

Edwards Lifesciences stock opened at $80.07 on Wednesday. The stock’s 50 day moving average price is $81.85 and its 200 day moving average price is $81.72. Edwards Lifesciences has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a market cap of $46.16 billion, a PE ratio of 43.75, a price-to-earnings-growth ratio of 2.07 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company’s revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the sale, the vice president directly owned 33,934 shares in the company, valued at $2,897,284.92. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 61,718 shares of company stock worth $5,236,281. Insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

A number of large investors have recently bought and sold shares of EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $266,000. Westerkirk Capital Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter valued at about $493,000. Beacon Pointe Advisors LLC lifted its holdings in Edwards Lifesciences by 3.4% in the 2nd quarter. Beacon Pointe Advisors LLC now owns 30,359 shares of the medical research company’s stock valued at $2,374,000 after purchasing an additional 995 shares in the last quarter. Groupe la Francaise boosted its stake in shares of Edwards Lifesciences by 719.4% during the 2nd quarter. Groupe la Francaise now owns 19,174 shares of the medical research company’s stock worth $1,493,000 after purchasing an additional 16,834 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $209,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.